Based on the findings of the BOLERO‐2 and BOLERO‐5 studies, everolimus has been approved by the FDA [12] and the NMPA for use in combination with exemestane to treat postmenopausal HR‐positive/HER2‐negative advanced breast cancer patients who have experienced treatment failure after letrozole or anastrozole therapy. This evidence concerns the gene ERBB2 and breast cancer.